Neuropsychological assessment and treatment possibilities of cognitive deficit in schizophrenic patients

Neuropsychological assessment and treatment possibilities of cognitive deficit in schizophrenic patients

nema

Bibliographic Details
Main Authors:	Totić-Poznanović Sanja, Pavlović Dragan M., Đorđević Jelena R., Pavlović Aleksandra M., Marinković Dragan
Format:	Article
Language:	English
Published:	Military Health Department, Ministry of Defance, Serbia 2012-01-01
Series:	Vojnosanitetski Pregled
Subjects:	schizophrenia cognition antipsychotic agents rehabilitation
Online Access:	http://www.doiserbia.nb.rs/img/doi/0042-8450/2012/0042-84501206510T.pdf

Similar Items

Social cognition in schizophrenia
by: Marinković Dragan, et al.
Published: (2011-01-01)

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia
by: Kristian S. Hill, et al.
Published: (2009-04-01)

Cigarette smoking and heavy coffee drinking affect therapeutic response to olanzapine
by: Radmanović Branimir, et al.
Published: (2018-01-01)

COGNITIVE AND NEUROPSYCHOLOGICAL FUNCTIONS IN SCHIZOPHRENIC PATIENTS, WHILE THE FIRST EPISODE
by: A EBRAHIMI, et al.
Published: (2003-12-01)

Alteration of Serum Levels of Cytokines in Schizophrenic Patients before and after Treatment with Risperidone
by: Esfandiar Azizi, et al.
Published: (2019-06-01)

The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review
by: Petru Fabian Lungu, et al.
Published: (2024-04-01)

Survey schizophrenic patients’ satisfaction with antipsychotic medication in Shafa ‎psychiatric center
by: naeima khodadady, et al.
Published: (2009-10-01)

Decision analytic economic paliperidone ER in relapsing schizophrenic patients in Italy
by: Patrizia Berto, et al.
Published: (2008-06-01)

Age-related changes of superoxide dismutase activity in patients with schizophrenia
by: Đorđević Vladimir V., et al.
Published: (2017-01-01)

A comparative study of sexual dysfunction in clinically stable schizophrenic patients receiving trifluoperazine, risperidone, and olanzapine
by: Rajesh Kumar Thakur, et al.
Published: (2023-05-01)

Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
by: Chadia Haddad, et al.
Published: (2023-01-01)

Notes from Underground: Are cognitive-enhancing drugs respecting their promises?
by: Frank Larøi, et al.
Published: (2010-09-01)

Symptomatic Resolution Among Chinese Patients With Schizophrenia and Associated Factors
by: Cheng-Ta Li, et al.
Published: (2010-05-01)

Clozapine: the past, present, and future
by: Sekh Afrar Alam, et al.
Published: (2015-07-01)

Retrospective analysis of hospitalization rates in patients with schizophrenia 12 months before and 12 months after the switch on once-monthly long-acting injectable paliperidone palmitate
by: Totić-Poznanović Sanja, et al.
Published: (2023-01-01)

Onset of Action of Selected Second-Generation Antipsychotics (Pines)–A Systematic Review and Meta-Analyses
by: Rikke Meyer, et al.
Published: (2022-12-01)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in Cognitive Impairment in Schizophrenia. A virtual human patient trial using Quantitative Systems Pharmacology
by: Hugo eGeerts, et al.
Published: (2015-09-01)

Modern approaches to the therapy of schizophrenia with atypical neuroleptics (based on clinical observations)
by: D. D. Samoylov, et al.
Published: (2024-12-01)

The Reality Monitoring Deficit as a Common Neuropsychological Correlate of Schizophrenic and Affective Psychosis
by: Enrico Smeraldi, et al.
Published: (2013-05-01)

Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics Dislipidemia aumentada em pacientes esquizofrênicos ambulatoriais em uso de antipsicóticos de nova geração
by: Carmen Lúcia Leitão-Azevedo, et al.
Published: (2006-12-01)

Neuropsychology, Social Cognition and Global Functioning Among Bipolar, Schizophrenic Patients and Healthy Controls: Preliminary Data
by: Elisabetta eCaletti, et al.
Published: (2013-10-01)

Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program
by: Carmen Gallastegui, et al.
Published: (2019-11-01)

A systematic review of the effects of psychiatric medications on social cognition
by: Zoë Haime, et al.
Published: (2021-11-01)

Sleep spindle deficits in antipsychotic-naïve early course schizophrenia and in non-psychotic first-degree relatives
by: Dara S Manoach, et al.
Published: (2014-10-01)

Loxapine in patient with clozapine-resistant psychosis
by: Jennifer Erley, PharmD, MBA, BCPS, et al.
Published: (2021-07-01)

Psychotic Disorders: Self-Directed Learning Module
by: Sarah Johnson, et al.
Published: (2014-12-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)

Effect of Atypical Antipsychotic Medications on the Risk of Obstructive Sleep Apnea in Individuals With Schizophrenia
by: Habibolah Khazaie, et al.
Published: (2022-09-01)

Executive functions in young patients with unipolar depression
by: Totić-Poznanović Sanja, et al.
Published: (2006-01-01)

Cognitive rehabilitation of neuropsychological deficits and mild cognitive impairment: A review of the literature
by: Eliane Correa Miotto, et al.

Management of cognitive and negative symptoms in schizophrenia
by: Megan Maroney, PharmD, BCPP
Published: (2022-11-01)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
by: Huang YC, et al.
Published: (2018-03-01)

Successful treatment with olanzapine and aripiprazole of a schizophrenic patient who developed priapism after switching from risperidone to paliperidone
by: Saki Kawahara, et al.
Published: (2024-12-01)

The effect of antipsychotic medication and the associated hyperprolactinemia as a risk factor for periodontal diseases in schizophrenic patients: a cohort retrospective study
by: Rania Shalaby, et al.
Published: (2023-10-01)

Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT
by: Liss Anda, et al.
Published: (2021-12-01)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020-11-01)

The altered volume of striatum: A neuroimaging marker of treatment in first-episode and drug-naïve schizophrenia
by: Gao-Xia Wei, et al.
Published: (2024-06-01)

Treatment of antipsychotic-induced parkinsonism in schizophrenic patients
by: E. E. Vaiman, et al.
Published: (2021-08-01)

Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis
by: Lena Feber, et al.
Published: (2023-03-01)

Prevalence of High Blood Pressure and its Relationship with Body Weight Factors among Inpatients with Schizophrenia in Taiwan
by: Yu-Li Lan, PhD, et al.
Published: (2012-03-01)